APMs can create problems for vulnerable populations

Patients with disabilities or living in poverty have poorer health outcomes and higher costs. Theoretically, alternative payment models (APMs) could encourage providers to better coordinate care for vulnerable populations and improve their outcomes—but they also have the potential to harm these patients, according to Karen Joynt Maddox, MD, MPH, assistant professor of medicine at Washington University in St. Louis.

Writing in the New England Journal of Medicine, Maddox said clinicians may have incentives in APMs to avoid high-risk patients thanks to risk adjustment which doesn’t separate lower quality care from socioeconomic risk.

“As a result, hospitals or clinics with a high proportion of poor patients may lose money under APMs through no fault of their own,” Maddox wrote. “Particularly in programs with a high level of downside financial risk, there is a powerful incentive for clinicians to avoid providing care for high-risk patients, which could have meaningful consequences for access to care.”

Some APMs, however, have shown evidence of helping this population. In the Medicare Shared Savings Program, for example, organizations which earned shared savings were more likely to serve a higher proportion of disabled or dual-eligible patients.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.